Literature DB >> 24001

Role of complement in lethal bacterial lipopolysaccharide-induced hypotensive and coagulative changes.

R J Ulevitch, C G Cochrane.   

Abstract

The effect of C3 depletion on the multiple pathophysiological changes produced by a lethal dose of Serratia marcescens lipopolysaccharide (LPS) was evaluated. The injection of this LPS into rabbits resulted in biphasic hypotensive changes and thrombocytopenia. These changes were characterized by an acute, transient decrease occurring within minutes after injection followed by a second more gradual decrease beginning 30 to 60 min post-LPS. Prior depletion of C3, with the anticomplementary protein from cobra venom (CoF), did not alter the extent of either the gradual hypotensive and platelet changes or the coagulative and metabolic changes when normal and C3-depleted rabbits were compared. Importantly, the lethal effects of S. marcescens LPS were not reduced by prior depletion of C3. Only the immediate, reversible thrombocytopenia and hypotension were abrogated by C3 depletion.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 24001      PMCID: PMC414068          DOI: 10.1128/iai.19.1.204-211.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Human factor XII (Hageman factor).

Authors:  J H Griffin; C G Cochrane
Journal:  Methods Enzymol       Date:  1976       Impact factor: 1.600

2.  The behaviour of complement and platelets in lethal endotoxin shock in rabbits.

Authors:  D L Brown; P J Lachmann
Journal:  Int Arch Allergy Appl Immunol       Date:  1973

3.  Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS).

Authors:  D C Morrison; L F Kline
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

Review 4.  Complement independent lipopolysaccharide (LPS) induced hypotension and disseminated intravascular coagulation: a correlation of LPS structure with in vivo and in vitro biological activities.

Authors:  R J Ulevitch; D C Morrison; C G Cochrane; P M Henson
Journal:  Adv Exp Med Biol       Date:  1976       Impact factor: 2.622

5.  The role of complement in endotoxin shock and disseminated intravascular coagulation: experimental observations in the dog.

Authors:  R Garner; B V Chater; D L Brown
Journal:  Br J Haematol       Date:  1974-11       Impact factor: 6.998

6.  Complement-dependent hemodynamic and hematologic changes in the rabbit.

Authors:  R J Ulevitch; C G Cochrane
Journal:  Inflammation       Date:  1977-09       Impact factor: 4.092

7.  Host resistance to lipopolysaccharides in the pathogenesis of multiple sclerosis and membranoproliferative glomerulonephritis.

Authors:  U Back; B B Moller; T C Bog-Hansen
Journal:  Lancet       Date:  1976-07-24       Impact factor: 79.321

8.  Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9.

Authors:  P J Lachmann; R A Thompson
Journal:  J Exp Med       Date:  1970-04-01       Impact factor: 14.307

9.  Mediation systems in bacterial lipopolysaccharide-induced hypotension and disseminated intravascular coagulation. I. The role of complement.

Authors:  R J Ulevitch; C G Cochrane; P M Henson; D C Morrison; W F Doe
Journal:  J Exp Med       Date:  1975-12-01       Impact factor: 14.307

10.  Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor.

Authors:  J Benveniste; P M Henson; C G Cochrane
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

View more
  10 in total

Review 1.  The effects of bacterial endotoxins on host mediation systems. A review.

Authors:  D C Morrison; R J Ulevitch
Journal:  Am J Pathol       Date:  1978-11       Impact factor: 4.307

Review 2.  Interaction of platelets with bacterial endotoxins.

Authors:  N Semeraro; A Lattanzio
Journal:  Agents Actions       Date:  1983-08

3.  The distribution of lipopolysaccharide in normocomplementemic and C3-depleted rabbits and rhesus monkeys.

Authors:  J C Mathison; R J Ulevitch; J R Fletcher; C G Cochrane
Journal:  Am J Pathol       Date:  1980-11       Impact factor: 4.307

4.  The effect of complement depletion on bacterial lipopolysaccharide (LPS)-induced hemodynamic and hematologic changes in the Rhesus monkey.

Authors:  R J Ulevitch; C G Cochrane; K Bangs; C M Herman; J R Fletcher; C L Rice
Journal:  Am J Pathol       Date:  1978-07       Impact factor: 4.307

5.  New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides.

Authors:  R J Ulevitch; A R Johnston; D B Weinstein
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

6.  Protection of mice against endotoxin-induced liver damage by anti-inflammatory drugs.

Authors:  J Ferluga; A Kaplun; A C Allison
Journal:  Agents Actions       Date:  1979-12

7.  Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death.

Authors:  H W Harris; C Grunfeld; K R Feingold; T E Read; J P Kane; A L Jones; E B Eichbaum; G F Bland; J H Rapp
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

8.  Complement and polymorphonuclear leukocytes do not determine the vascular permeability induced by intraocular LPS.

Authors:  E L Howes; K L Wong; K T Hartiala; R O Webster; J T Rosenbaum
Journal:  Am J Pathol       Date:  1985-01       Impact factor: 4.307

9.  Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits.

Authors:  J C Mathison; E Wolfson; R J Ulevitch
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

10.  The third component of complement protects against Escherichia coli endotoxin-induced shock and multiple organ failure.

Authors:  Z M Quezado; W D Hoffman; J A Winkelstein; I Yatsiv; C A Koev; L C Cork; R J Elin; P Q Eichacker; C Natanson
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.